BACKGROUND: Charcot-Marie-Tooth disease (CMT) is the most common inherited neuropathy. CMT is classified into 2 main subgroups: CMT type 1 (CMT1; demyelinating form) and CMT type 2 (CMT2; axonal form). The objectives of this study were to systematically review and assess the quality of studies reporting the incidence and/or prevalence of CMT worldwide. SUMMARY: A total of 802 studies were initially identified, with only 12 meeting the inclusion criteria. CMT prevalence was reported in 10 studies and ranged from 9.7/100,000 in Serbia to 82.3/100,000 in Norway. The frequency of the main subtypes varied from 37.6 to 84% for CMT1 and from 12 to 35.9% for CMT2; the country with the lowest prevalence of CMT1 was Norway, and the country with the highest prevalence of CMT1 was Iceland; on the other hand, CMT2 was least prevalent in the United Kingdom and most prevalent in Norway. KEY MESSAGES: This review reveals the gaps that still exist in the epidemiological knowledge of CMT around the world. Published studies are of varying quality and utilise different methodologies, thus precluding a robust conclusion. Additional research focusing on epidemiological features of CMT in different nations and different ethnic groups is needed.
BACKGROUND:Charcot-Marie-Tooth disease (CMT) is the most common inherited neuropathy. CMT is classified into 2 main subgroups: CMT type 1 (CMT1; demyelinating form) and CMT type 2 (CMT2; axonal form). The objectives of this study were to systematically review and assess the quality of studies reporting the incidence and/or prevalence of CMT worldwide. SUMMARY: A total of 802 studies were initially identified, with only 12 meeting the inclusion criteria. CMT prevalence was reported in 10 studies and ranged from 9.7/100,000 in Serbia to 82.3/100,000 in Norway. The frequency of the main subtypes varied from 37.6 to 84% for CMT1 and from 12 to 35.9% for CMT2; the country with the lowest prevalence of CMT1 was Norway, and the country with the highest prevalence of CMT1 was Iceland; on the other hand, CMT2 was least prevalent in the United Kingdom and most prevalent in Norway. KEY MESSAGES: This review reveals the gaps that still exist in the epidemiological knowledge of CMT around the world. Published studies are of varying quality and utilise different methodologies, thus precluding a robust conclusion. Additional research focusing on epidemiological features of CMT in different nations and different ethnic groups is needed.
Authors: Sergio Tejero; Juan Chans-Veres; Andrés Carranza-Bencano; Ahmed E Galhoum; Daniel Poggio; Victor Valderrábano; Mario Herrera-Pérez Journal: Int Orthop Date: 2021-02-21 Impact factor: 3.075
Authors: Diana C Lee; Lois Dankwa; Christyn Edmundson; David R Cornblath; Steven S Scherer Journal: J Peripher Nerv Syst Date: 2019-11-19 Impact factor: 3.494
Authors: Ilaria Callegari; C Gemelli; A Geroldi; F Veneri; P Mandich; M D'Antonio; D Pareyson; M E Shy; A Schenone; V Prada; M Grandis Journal: J Neurol Date: 2019-07-05 Impact factor: 4.849
Authors: Jennifer G Le-Rademacher; Camden L Lopez; Rahul Kanwar; Brittny Major-Elechi; Alexej Abyzov; Michaela S Banck; Terry M Therneau; Jeff A Sloan; Charles L Loprinzi; Andreas S Beutler Journal: J Neurol Sci Date: 2020-01-14 Impact factor: 3.181